Cargando…

Conjunctival T Cell Profile in Allogeneic Hematopoietic Stem Cell Transplant Patients after Instilling Topical Cyclosporine-A 0.1% Cationic Emulsion

INTRODUCTION: To profile conjunctival T cell populations in allogeneic hematopoietic stem cell transplant (HSCT) patients after instillation of daily topical cyclosporine-A (CsA) 0.1% cationic emulsion (Ikervis), and to evaluate patients’ tolerance to these eye drops. METHODS: Nineteen participants...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tong, Louis, Lim, Elizabeth Wen Ling, Yeo, Sharon Wan Jie, Hou, Aihua, Linn, Yeh Ching, Ho, Aloysius, Than, Hein, Quek, Jeffrey Kim Siang, Hwang, William Ying Khee, Lim, Francesca Lorraine Wei Inng, Lim, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164203/ https://www.ncbi.nlm.nih.gov/pubmed/36856978 http://dx.doi.org/10.1007/s40123-023-00686-0

Ejemplares similares

Comparative analysis of 0.1% cyclosporin A cationic emulsion and 0.05% cyclosporin A emulsion in murine dry eye cases with different severities
por: Jin, Rujun, et al.
Publicado: (2021)

One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease
por: Baudouin, Christophe, et al.
Publicado: (2017)

A Randomized Study of the Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in Treatment of Moderate to Severe Dry Eye
por: Baudouin, Christophe, et al.
Publicado: (2017)

Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment
por: Geerling, Gerd, et al.
Publicado: (2022)

Assessment of the efficacy of 0.1% cyclosporine A cationic emulsion in the treatment of dry eye disease during COVID-19 pandemic
por: Stopyra, Wiktor
Publicado: (2023)

A proposed predictive mathematical model for efficient T-cell collection by leukapheresis for manufacturing chimeric antigen receptor T cells
por: Huang, Xinxin, et al.
Publicado: (2023)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
por: Matossian, Cynthia, et al.
Publicado: (2021)

HEMATOPOIETIC STEM CELL TRANSPLANT IN AGGRESSIVE T AND NK/T CELL LYMPHOMA - ROLE OF UPFRONT AUTOLOGOUS TRANSPLANT IN NODAL PERIPHERAL T-CELL LYMPHOMA
por: Cheng Kiat Ng, Lawrence, et al.
Publicado: (2021)

Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program
por: Pisella, Pierre-Jean, et al.
Publicado: (2018)

Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit model
por: Liang, Hong, et al.
Publicado: (2012)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade, Vinod, et al.
Publicado: (2020)

Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials
por: Leonardi, Andrea, et al.
Publicado: (2022)

Clinical Outcomes of Topical 0.1% Ciclosporin Cationic Emulsion Used on Label in Children with Vernal Keratoconjunctivitis
por: Giannaccare, Giuseppe, et al.
Publicado: (2023)

CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity
por: Tan, Jing Yuan, et al.
Publicado: (2022)

Efficacy and Safety of 0.1% Cyclosporine versus 2% Cyclosporine in the Treatment of Severe Vernal Keratoconjunctivitis in Children
por: Bourcier, Tristan, et al.
Publicado: (2022)

Histopathological changes in the lungs of rats instilled with Korean chrysotile
por: Han, Jeong Hee, et al.
Publicado: (2021)

Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
por: Nebbioso, Marcella, et al.
Publicado: (2019)

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

Real World Favourable Experience of Haematopoietic Stem Cell Transplantation during Acute Coronavirus Disease 2019 in a Highly-Vaccinated Asian Population
por: Tham, Christopher, et al.
Publicado: (2022)

Management of XEN Gel Stent Exposure with Conjunctival Erosion via Rotational Conjunctival Flap and Amniotic Membrane Transplantation—A Case Report
por: Lee, Chang Kyu, et al.
Publicado: (2022)

Effectiveness of Topical Cyclosporin-A 0.1% Compared to Combined Topical Cyclosporin-A 0.1% with Topical Sodium Hyaluronate on Interleukin-6 Levels in the Tears of Patients with Dry Eye Disease
por: Priani, Desti, et al.
Publicado: (2023)

Influence of cyclosporine A on glomerular growth and the effect of mizoribine and losartan on cyclosporine nephrotoxicity in young rats
por: Kim, Ji Hong, et al.
Publicado: (2016)

Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen
por: Chan, Yuan-Hsi, et al.
Publicado: (2023)

Conjunctival melanoma: a review of conceptual and treatment advances
por: Lim, Li-Anne, et al.
Publicado: (2013)

Pseudomembranous Conjunctivitis: A Possible Conjunctival Foreign Body Aetiology
por: Ho, Dawn, et al.
Publicado: (2020)

Post Laparoscopy Pain Reduction Project I (POLYPREP I): intraperitoneal normal saline instillation—a randomised controlled trial
por: Adlan, Aizura Syafinaz Ahmad, et al.
Publicado: (2022)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

First Reported Case of Rhabdomyolysis Associated with Concomitant Use of Cyclosporin, Diltiazem, and Simvastatin
por: Fuah, Kar Wah, et al.
Publicado: (2021)

Health claims database study of cyclosporine ophthalmic emulsion treatment patterns in dry eye patients
por: Stonecipher, Karl G, et al.
Publicado: (2013)

Optimization and physicochemical characterization of a cationic lipid-phosphatidylcholine mixed emulsion formulated as a highly efficient vehicle that facilitates adenoviral gene transfer
por: Kim, Soo-Yeon, et al.
Publicado: (2017)

Short-Term Changes in Tear Lipid Layer Thickness After Instillation of Lipid Containing Eye Drops
por: Lim, Phoebe, et al.
Publicado: (2020)

Conjunctival erosion following a PRESERFLO® MicroShunt procedure
por: Fahy, Eamonn T., et al.
Publicado: (2022)

Effects of 0.01% Atropine Instillation Assessed Using Swept-Source Anterior Segment Optical Coherence Tomography
por: Mitsukawa, Tadahiro, et al.
Publicado: (2021)

Frequency and Risk Factors of Cyclosporine-Induced Neurotoxicity in Allogeneic Stem Cell Transplant Recipients
por: Danish, Asma, et al.
Publicado: (2021)

Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsion
por: Karn, Pankaj Ranjan, et al.
Publicado: (2014)

Cationic Emulsion Polymerization of Octamethylcyclotetrasiloxane (D4) in Mixtures with Alkoxysilanes
por: Kozakiewicz, Janusz, et al.
Publicado: (2022)

A Prospective Study of Cyclosporine A 0.1% Combined with Loteprednol 0.2% vs Cyclosporine A 0.05% Alone in the Treatment of Dry Eye
por: Hovanesian, John, et al.
Publicado: (2023)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney, Tatiana, et al.
Publicado: (2018)

Immunoglobulin Heavy Chain Gene Rearrangement Studies in the Diagnosis of a Paediatric Conjunctival Lesion
por: Lim, Benjamin Cheuk Hung, et al.
Publicado: (2019)

Optimization Conditions to Obtain Cationic Polyacrylamide Emulsion Copolymers with Desired Cationic Degree for Different Wastewater Treatments
por: Nguyen, Tung Huy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s8mj7l7n6t3019dp43ts3n4tbv